On a non-GAAP basis, excluding stock-compensation expense, the net loss from continuing operations for the 2010 second quarter was $3.3 million or $0.20 per ordinary share. This compares with a non-GAAP net loss from continuing operations for the 2009 second quarter of $3.5 million or $0.26 per ordinary share.For the six months ended June 30, 2010 the Company reported revenues from continuing operations of $97,000, compared with revenues from continuing operations of $31,000 in the comparable prior year period. The Company’s net loss from continuing operations in the first half of 2010 was $7.8 million or $0.48 per ordinary share, compared with a net loss from continuing operations of $7.2 million or $0.56 per ordinary share in the same period of 2009.
Rosetta Genomics Reports Second Quarter 2010 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.